BACKGROUND: The use of invasive procedures has mostly been studied in retrospective (multi)- national registries. Limited evidence exists on the association between microalbuminuria and coronary artery disease (CAD). METHODS: The incidence of major adverse cardiac events (MACE) and invasive cardiac procedures was registered between 1997 and 2003 in 8139 subjects, without prior documented CAD, in the PREVEND cohort study (the Netherlands), in which the focus is on microalbuminuria and cardiovascular risk. Qualitative coronary angiographic analysis was performed. RESULTS: During 5.5 years of follow-up, a first MACE occurred in 271 (3.3%) and a first coronary angiography (CAG) was performed in 264 (3.2%) subjects. Of these, 216 CAGs were available for qualitative angiographic analysis. Indications for CAG were stable angina in 129, acute coronary syndrome (ACS) in 55 and ST-elevation myocardial infarction (STEMI) in 32 subjects. Obstructive coronary artery disease was present in 61, 53 and 30 subjects, respectively. A revascularisation was performed in 50 (39%), 50 (91%) and 25 (78%) subjects, respectively. Microalbuminuria was associated with a first MACE, after adjustment for established risk factors. Microalbuminuria was present at baseline in 9% of subjects with normal coronary arteries, in 21% of subjects with one- and two-vessel CAD and in 39% of subjects with threevessel or left main CAD at CAG during follow-up (Ptrend=0.005). CONCLUSION: This large cohort study shows that two-thirds of diagnostic CAGs for stable angina were not followed by a revascularisation, in contrast to CAGs for STEMI or ACS. Furthermore, this study shows that microalbuminuria is associated with CAD. (Neth Heart J 2007;15:133-41.).
BACKGROUND: The use of invasive procedures has mostly been studied in retrospective (multi)- national registries. Limited evidence exists on the association between microalbuminuria and coronary artery disease (CAD). METHODS: The incidence of major adverse cardiac events (MACE) and invasive cardiac procedures was registered between 1997 and 2003 in 8139 subjects, without prior documented CAD, in the PREVEND cohort study (the Netherlands), in which the focus is on microalbuminuria and cardiovascular risk. Qualitative coronary angiographic analysis was performed. RESULTS: During 5.5 years of follow-up, a first MACE occurred in 271 (3.3%) and a first coronary angiography (CAG) was performed in 264 (3.2%) subjects. Of these, 216 CAGs were available for qualitative angiographic analysis. Indications for CAG were stable angina in 129, acute coronary syndrome (ACS) in 55 and ST-elevation myocardial infarction (STEMI) in 32 subjects. Obstructive coronary artery disease was present in 61, 53 and 30 subjects, respectively. A revascularisation was performed in 50 (39%), 50 (91%) and 25 (78%) subjects, respectively. Microalbuminuria was associated with a first MACE, after adjustment for established risk factors. Microalbuminuria was present at baseline in 9% of subjects with normal coronary arteries, in 21% of subjects with one- and two-vessel CAD and in 39% of subjects with threevessel or left main CAD at CAG during follow-up (Ptrend=0.005). CONCLUSION: This large cohort study shows that two-thirds of diagnostic CAGs for stable angina were not followed by a revascularisation, in contrast to CAGs for STEMI or ACS. Furthermore, this study shows that microalbuminuria is associated with CAD. (Neth Heart J 2007;15:133-41.).
Authors: P J Scanlon; D P Faxon; A M Audet; B Carabello; G J Dehmer; K A Eagle; R D Legako; D F Leon; J A Murray; S E Nissen; C J Pepine; R M Watson; J L Ritchie; R J Gibbons; M D Cheitlin; T J Gardner; A Garson; R O Russell; T J Ryan; S C Smith Journal: J Am Coll Cardiol Date: 1999-05 Impact factor: 24.094
Authors: Hans L Hillege; Vaclav Fidler; Gilles F H Diercks; Wiek H van Gilst; Dick de Zeeuw; Dirk J van Veldhuisen; Rijk O B Gans; Wilbert M T Janssen; Diederick E Grobbee; Paul E de Jong Journal: Circulation Date: 2002-10-01 Impact factor: 29.690
Authors: D Hasdai; S Behar; L Wallentin; N Danchin; A K Gitt; E Boersma; P M Fioretti; M L Simoons; A Battler Journal: Eur Heart J Date: 2002-08 Impact factor: 29.983
Authors: Tom D J Smilde; Folkert W Asselbergs; Hans L Hillege; Adriaan A Voors; Jan A Kors; Ron T Gansevoort; Wiek H van Gilst; Paul E de Jong; Dirk J Van Veldhuisen Journal: Am J Hypertens Date: 2005-03 Impact factor: 2.689
Authors: A Jager; P J Kostense; H G Ruhé; R J Heine; G Nijpels; J M Dekker; L M Bouter; C D Stehouwer Journal: Arterioscler Thromb Vasc Biol Date: 1999-03 Impact factor: 8.311
Authors: G Filardo; A P Maggioni; G Mura; F Valagussa; L Valagussa; C Schweiger; D J Ballard; A Liberati Journal: Eur Heart J Date: 2001-04 Impact factor: 29.983
Authors: C A Geluk; R A Tio; J G P Tijssen; R B van Dijk; W A Dijk; H L Hillege; P E de Jong; W H van Gilst; F Zijlstra Journal: Neth Heart J Date: 2007 Impact factor: 2.380
Authors: Qiao Zhao; Sabine J L Nooren; Laurien E Zijlstra; Jos J M Westenberg; Lucia J M Kroft; J Wouter Jukema; Noeleen C Berkhout-Byrne; Ton J Rabelink; Anton Jan van Zonneveld; Marjolijn van Buren; Simon P Mooijaart; Roel Bijkerk Journal: Noncoding RNA Date: 2022-01-10
Authors: Christiane A Geluk; Riksta Dikkers; Jan A Kors; René A Tio; Riemer H J A Slart; Rozemarijn Vliegenthart; Hans L Hillege; Tineke P Willems; Paul E de Jong; Wiek H van Gilst; Matthijs Oudkerk; Felix Zijlstra Journal: BMC Cardiovasc Disord Date: 2007-07-13 Impact factor: 2.298